Terminated PHASE1 INTERVENTIONAL 5-arm NCT00637403

Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension

An Open-Label, Single-Dose Study to Assess the Effect of Renal Impairment on the Pharmacokinetic Characteristics, Safety, and Tolerability of Megestrol Acetate

Sponsor: Covance

Conditions Healthy

Interventions Megestrol acetate concentrated suspension 125 mg/mL

Updated 6 times since 2017 Last updated: Oct 13, 2016 Started: May 31, 2006 Primary completion: May 31, 2006 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficulty finding the required subject population

Other terminated trials from Covance

See all terminations from Covance

Other Healthy trials with similar outcome

Browse all Healthy trials

Listed as NCT00637403, this PHASE1 trial focuses on Healthy and remains terminated or withdrawn. Sponsored by Covance, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Covance
Par Pharmaceutical, Inc.
SFBC Anapharm

Data source: Par Pharmaceutical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States